ESMO SUMMIT MIDDLE EAST 2018
|
|
- Cora Hill
- 5 years ago
- Views:
Transcription
1 ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE
2 CONFLICT OF INTEREST DISCLOSURE No conflict of interest
3 CASE 1: Treatment-naïve ER+ metastatic breast cancer in premenopausal woman CASE 2 : Adjuvant treatment in TNBC CASE 3 : Heavily pretreated HER2+ metastatic breast cancer CASE 4 : Heavily pretreated ER+ metastatic breast cancer CASE 5: Hereditary breast cancer CASE 6 : Metastatic breast cancer in man
4 CASE 1 : ER+ METASTATIC BREAST CANCER IN PRE- MENOPAUSAL WOMAN
5 CASE 1 : ER+ METASTATIC BREAST CANCER IN PRE- MENOPAUSAL WOMAN HISTORY AND SYMPTOMS 40 years old woman (born in 1978) without relevant past medical history Familial History : Mother diagnosed with a breast cancer at the age of 60 and a maternal cousin with breast cancer at the age of 50 She felt a right breast nodule, 4 years ago, (2014) during her pregnancy, without doing any further investigation She presented a dorsal pain since November 2017
6 CASE 1 : ER+ METASTATIC BREAST CANCER IN PRE- MENOPAUSAL WOMAN WORK-UP In the end of January 2018, she visited an orthopedic surgeon for investigation Persistant dorsal and lumbar pain despite the antalgic treatment Dorso-lombar MRI : secondary lesions at D12 and L2
7 CASE 1 : ER+ METASTATIC BREAST CANCER IN PRE- MENOPAUSAL WOMAN WORK-UP Mammogram : 4 cm lesion in the right breast with supra-centimetric axillary lymph nodes TAP CT Scan : no other secondary lesion Ca 15-3 : (N)
8 CASE 1 : ER+ METASTATIC BREAST CANCER IN PRE- MENOPAUSAL WOMAN WORK-UP Biopsy of the right breast nodule (2/2/2018) : Invasive ductal carcinoma moderately differentiated ER : positive (80%) PR : negative HER2 2+ FISH negative Ki67 : 25% Grade 2
9 Persistant dorsal pain without any response to antalgic treatment in ER+ metastatic breast cancer What to do next?
10 POSSIBLE THERAPEUTIC OPTIONS? 1)Chemotherapy followed by hormonal therapy 2)Radiation therapy followed by hormonal therapy 3)Hormonal therapy 4)Breast Surgery followed by hormonal therapy
11 REMOVAL OF THE PRIMARY IN METASTATIC BREAST CANCER
12 Radiation therapy on D12 and L2 vertebral secondary lesions (10 sessions) + Zoledronic acid What to do next?
13 POSSIBLE THERAPEUTIC OPTIONS? 1)LHRH agonists + AI 2)LHRH agonists + AI+ anti-cdk4/6 3)Bilateral oophorectomy + AI 4)Bilateral oophorectomy + AI + anti-cdk4/6 5)Tamoxifene 6)LHRH agonists + tamoxifene 7)LHRH agonists + tamoxifene + anti-cdk4/6
14 OVARIAN ABLATION VERSUS SUPPRESSION
15 eupdate ESMO Advanced Breast Cancer Algorithms, 2017
16 MONALEESA-7: Phase III placebo-controlled study of ribociclib and tamoxifen/nsai + goserelin Pre/perimenopausal women with HR+, HER2 ABC No prior endocrine therapy for advanced disease 1 line of chemotherapy for advanced disease N=672 Randomization (1:1) Stratified by: Presence/absence of liver/lung metastases Prior chemotherapy for advanced disease Endocrine therapy partner (tamoxifen vs NSAI) Ribociclib (600 mg/day; 3-weeks-on/1-weekoff) + tamoxifen/nsai + goserelin* n=335 Placebo + tamoxifen/nsai + goserelin* n=337 Primary endpoint PFS (locally assessed per RECIST v1.1) Secondary endpoints Overall survival (key) Overall response rate Clinical benefit rate Safety Patient-reported outcomes Tumor assessments were performed every 8 weeks for 18 months, then every 12 weeks thereafter Primary analysis planned after ~329 PFS events 95% power to detect a 33% risk reduction (hazard ratio 0.67) with one-sided α=2.5%, corresponding to an increase in median PFS to 13.4 months (median PFS of 9 months for the placebo arm 1,2 ), and a sample size of 660 patients Tripathy et al, SABCS 2017 NSAI, non-steroidal aromatase inhibitor; RECIST, Response Evaluation Criteria in Solid Tumors. *Tamoxifen = 20 mg/day; NSAI: anastrozole = 1 mg/day or letrozole = 2.5 mg/day; goserelin = 3.6 mg every 28 days; PFS by Blinded Independent Review Committee conducted to support the primary endpoint. 1. Klijn JG, et al. J Clin Oncol 2001;19: ; 2. Mourisden H, et al. J Clin Oncol 2001;19:
17 Probability of PFS (%) PRIMARY ENDPOINT: PFS (INVESTIGATOR-ASSESSED) PFS (investigator Ribociclib + tamoxifen/nsai Placebo + tamoxifen/nsai assessment) n=335 n=337 Number of events, n (%) 131 (39.1) 187 (55.5) Median PFS, months (95% CI) 23.8 (19.2 NR) 13.0 ( ) Hazard ratio (95% CI) ( ) One-sided p value No. at risk Time (months) Ribociclib + tamoxifen/nsai Placebo + tamoxifen/nsai Tripathy et al, SABCS 2017 CI, confidence interval; NR, not reached. Goserelin included in all combinations.
18 TREATMENT 16/3/2018 : bilateral oophorectomy 19/3/2018 : Started letrozole + palbociclib + zoledronic acid
19 UNMET NEED IN PREMENOPAUSAL PATIENTS WITH HR+, HER2 ABC Estimates suggest that in 2017 in the US, ~19% of invasive breast cancers will be diagnosed in women aged 49 years The proportion of patients aged <50 years may be up to 40% to 50% in the Middle East (Najjar et al) The last randomized trial focusing solely on premenopausal women with ABC was published in 2000 Young women with ABC have a distinct tumor biology, experience more aggressive disease, and are more likely to die from their cancer than older women
20 TAKE HOME MESSAGES FROM CASE ONE Premenopausal breast cancer patients represent an important public health issue in the Middle East More studies should be done in this specific population, mainly in developing countries Anti-CDK4/6 agents will certainly have their place in the algorithm of the treatment of pre-menopausal ER+ metastatic breast cancer
21 CASE 2 : ADJUVANT TREATMENT IN TNBC
22 HISTORY AND WORK-UP A 37 years old woman (born in 1981) without relevant past medical history Ultrasound of the left breast (24/1/2018) : an inferior-intern nodule of 1.8 cm (ACR4a) Breast MRI (8/2/2018) : an inferior-intern nodule of 2 cm ACR6 at left (ACR6) A biopsy was done (9/2/2018) :ductal carcinoma of unknown specificity (aspects of metaplastic carcinoma); ki67 : 70%, triple negative, grade 3
23 TUMORECTOMY 19/2/2018 : Tumorectomy Invasive ductal carcinoma, metaplastic with a squamous cell component and a ductal carcinoma NOS, grade 3, T=2.4 cm Negative margins 0/10 positive lymph nodes Absence of vascular and lymphatic invasion
24 WORK-UP PET/CTScan : negative Cardiac US : EF=70% Genetic testing : ongoing
25 HISTOLOGIC SUBTYPES : INFILTRATIVE CARCINOMA
26 METAPLASTIC CARCINOMA RARE POOR PROGNOSIS CHEMORESISTANT?
27 IN FRONT OF TNBC WITH METAPLASTIC COMPONENT? 1)SURVEILLANCE 2)ADJUVANT CHEMOTHERAPY 3)RADICAL MASTECTOMY
28 It was decided to start a chemotherapy. Dose Dense versus every 3 weeks adjuvant chemotherapy?
29 San Antonio 2017
30
31 Is there any role for carboplatine in the adjuvant setting if there is a BRCA mutation?
32 CARBOPLATIN BASED REGIMEN IN THE NEO- ADJUVANT SETTING Castrellon et al, 2017
33 TWO NEGATIVE TRIALS IN THE ADJUVANT SETTING ASCO 2017
34 TAKE HOME MESSAGES FROM CASE 2 TNBC is divided in different histologic and molecular subtypes ; each one having specific characteristics Dose-dense chemotherapy could be considered in the adjuvant setting, namely in TNBC 5% decrease in recurrence rate at 10 years No evidence on the use of carboplatine in the adjuvant setting in BRCA mutated triple negative breast cancer
35 CASE 3 : HEAVILY TREATED HER2+ MBC 55 years old women, without past medical history or comorbidities, diagnosed in 2003 with right breast cancer. Tumorectomy ; pathology : DCIS of 3.5 cm with positive margins, ER 8/8, PR 0/8 and HER2 3+ Right mastectomy
36 HISTORY 55 years old women, without past medical history or comorbidities, diagnosed in 2003 with right breast cancer. Tumorectomy ; pathology : DCIS of 3.5 cm with positive margins, ER 8/8, PR 0/8 and HER2 3+ Right mastectomy
37
38
39
40
41
42 \
43
44 OTHER POSSIBLE TREATMENT OPTIONS Eribuline role? with trastuzumab? Platinum-based agents? A place for pertuzumab in heavily pre-treated HER2+ patients?
45
46 HER2 + BC WITH BRAIN METASTASES
47 SUPPRESSION OF ANTI-HER2 PATHWAY
48 CASE 4 : HEAVILY TREATED PREMENOPAUSAL HR+ MBC
49 HISTORY AND DIAGNOSIS 45 years old woman, without past medical history, diagnosed in 1999 at the age of 28 with right breast cancer Tumorectomy + lymph node dissection : hormonal receptors and negative HER2 22 mm invasive ductal carcinoma with positive Familial history : Absence of other cancers in the family Genetic screening : Absence of BRCA1 or BRCA2 mutation
50 ADJUVANT TREATMENT Followed by adjuvant chemotherapy 4 adriamycine and 3 MF, radiation therapy and tamoxifen (stopped in 2001, after 1 year for pregnancy and restarted after that) 3MF instead of CMF : cyclophosphamide was omitted in order to decrease the risk of toxicity to the ovaries
51 PREMENOPAUSAL LUMINAL BREAST CANCER-PREGNANCY Fertility concerns influence treatment decision in an important number of patients Many patients still fear that a future pregnancy will increase their risk of recurrence
52 POSITIVE TRIAL BIG - Patients with ER+ early breast cancer - 42 years at enrolment - Completing months of ET (SERMs alone, LH-RH analogue + SERM or AIs) - Pregnancy desire ClinicalTrials.gov. Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Response Breast Cancer (POSITIVE). NCT Accessed December 21, 2015.
53
54
55
56 The patient presented a new bone marrow progression. Suggestions? New agents Experimental therapy (phase 1?) Other?
57 Treatment by aromatase inhibitor (started 6/1/2016) and palbociclib (22/1/2016) Schedule of Palbociclib was adapted according to hematogical count during therapy
58 Good performance status during the evolution of the disease and willing to be actively treated. In addition to standard of care, access to 3 new therapies that become available during the course of the disease (eribuline, afinitor and palbociclib) and 1 experimental agent (XRP). Long ambulatory course treatment of 17 years (Her child become an adolescent of 16 years at her death) Hospitalized only for 2 times One episode of febrile neutropenia (March 2016) Death due to hepatic PD (April 2016 )
59 CASE 5 : HEREDITARY CANCERS
60 HISTORY Mrs R is a single woman, without a relevant past medical history, diagnosed at the age of 40 from a breast cancer.
61 PEDIGREE? Eugénie, Lung? Elias Lena, Melanoma at 60 Najib Suzanne, breast cancer at the age of 50 Fouad 3 2 Tony,prostate cancer at 64 Michel 5 Rabiha, CUP at 27 years old Wadih, 1939,died in 2011 Souad 1950 Jean, melanoma at the age 64 died at the age of 68 Maroun 1968 Joseph 1969 Simon 1972 Rania
62 DIAGNOSIS Pathology report (2014) : Triple negative invasive ductal carcinoma, grade 3. T=1.8cm without lymph node invasion.
63 TREATMENT Treated with neo-adjuvant chemotherapy (4AC-4T) followed by partial mastectomy and radiation therapy. She relapsed in 2016 and presented a single pulmonary nodule of 1.2 cm, treated by surgery. Now she is under surveillance.
64 Is there any indication for genetic testing? Which genes should be tested?
65
66 WHEN WE SHOULD SUSPECT A HEREDITARY BREAST CANCER IN A PATIENT WITH BREAST CANCER?
67 HEREDITARY BREAST CANCER GENE PANEL
68 RESULTS OF GENETIC TESTING Panel of 19 genes for breast ovarian hereditary cancer panel Presence of pathogenic BRCA1 mutation
69 CONSEQUENCES ON THE PATIENT AND HIS FAMILY Prophylactic bilateral mastectomy and salpingo-oophorectomy Targeted genetic testing in the children and brotherhood
70 PREVENTION AND SCREENING IN BRCA MUTATION CARRIERS AND OTHER BREAST/OVARIAN HEREDITARY CANCER SYNDROMES: ESMO CLINICAL PRACTICE GUIDELINES Paluch-Shimon et al, Annals of Oncology 2016
71 PREVENTION AND SCREENING IN BRCA MUTATION CARRIERS AND OTHER BREAST/OVARIAN HEREDITARY CANCER SYNDROMES: ESMO CLINICAL PRACTICE GUIDELINES Breast cancer risk reduction screening Paluch-Shimon et al, Annals of Oncology 2016
72 PREVENTION AND SCREENING IN BRCA MUTATION CARRIERS AND OTHER BREAST/OVARIAN HEREDITARY CANCER SYNDROMES: ESMO CLINICAL PRACTICE GUIDELINES Breast cancer risk reduction surgery Paluch-Shimon et al, Annals of Oncology 2016
73 OTHER BRCA-ASSOCIATED CANCER Paluch-Shimon et al, Annals of Oncology 2016
74 PREVENTION AND SCREENING STRATEGIES FOR SPECIFIC MUTATIONS Paluch-Shimon et al, Annals of Oncology 2016
75 TAKE HOME MESSAGES FOR CASE 5 Genetic counseling is necessary in : -patients with familial history of breast and ovarian cancer, -young patients with breast cancers -patient with more than one cancer from the spectrum of HBOC. Panel of genes for HBOC syndrome by NGS Prophylactic screening modalities and surgey are indicated in the presence of deleterious mutations leading to HBOC syndrome
76 CASE 6 : METASTATIC BREAST CANCER IN MALE
77 HISTORY A 43 years old patient (born in 1975) without relevant past medical history No familial history of cancer
78 DIAGNOSIS October 2016 : palpation of a lump in the right breast Total body MRI done showed a 4.4 cm nodule in the with axillary lymph nodes, 2 costal secondary lesions and diffuse small pulmonary nodules (<5 mm)
79 PATHOLOGY REPORT Invasive ductal carcinoma ER : 75% PR : 10% HER2 :- Grade 2
80 TREATMENT November 2016: He was treated with letrozole and palbociclib February 2017: Partial response ; breast lesion decreased to 2.8 cm instead of 4.4 cm ; disapparance of costal lesions, decrease and disappearance of lung lesions
81
82 In april 2018, after 18 months of treatment by letrozole and palbociclib, he presented a progression in the axillary lymph nodes (+20%) and appearance of a new bone lesion and progression of the costal lesions The patient tolerated very well the treatment without remarkable side effects
83
84 FEW CASES REPORTED IN THE LITERATURE ASCO 2017
85 What is the treatment option after progression?
86 eupdate ESMO Advanced Breast Cancer Algorithms, 2017
87 What is the treatment option after progression?
88 TAKE HOME MESSAGES A genetic counseling is necessary in every man with breast cancer Second line hormonal-based treatment is indicated after progression on 1 st line ER+ metastatic breast cancer in the absence of visceral crisis Extrapolation of the treatment of breast cancer in men from women
89 THANK YOU
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationMONALESSA-7: Phase III placebo-controlled study of ribociclib and tamoxifen/nsai + goserelin
First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer:
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationFigure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.
Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationMETASTATIC BREAST CANCER: CONTROLLING THE HERD WHEN THE HORSES ARE OUT OF THE BARN
METASTATIC BREAST CANCER: CONTROLLING THE HERD WHEN THE HORSES ARE OUT OF THE BARN V A L L E R I E G O R D O N B S C, M D, F R C P C M E D I C A L O N C O L O G I S T A S S I S T A N T P R O F E S S O
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationAdjuvant endocrine therapy (essentials in ER positive early breast cancer)
Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine
More informationPregnancy in the middle of adjuvant treatment of Her2 positive breast cancer
ESMO Preceptorship Programme ESMO Preceptorship ADOLESCENTS & YOUNG ADULTS MALIGNANCIES Lugano, Switzerland 11-12 May 2018 Petra Vuković, University Hospital for Tumors, University Hospital Center Sestre
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationCollaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer Lee Schwartzberg, MD, FACP Heather Greene, FNP, AOCNP West Cancer Center Memphis, Tennessee Learning Objectives
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationUpdate from the 29th Annual San Antonio Breast Cancer Symposium
Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,
More information